Zacks Investment Research downgraded shares of VERENIUM CORP (VRNM) from NEUTRAL to UNDERPERFORM on November 15, 2012, with a target price of $2.20.
Verenium Corporation is engaged in the development and commercialization of high-performance enzymes for use in industrial processes. The Company sells its developed enzymes to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes. It uses unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on VERENIUM CORP (VRNM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment